Refine by
Stem Cell Transplant Suppliers & Manufacturers
28 companies found
Premium
based inDueren, GERMANY
Since 2005, NIPPON Genetics EUROPE has stood for innovation and quality in biotechnology. In these two decades, we have evolved from a supplier of high quality Japanese technologies to a developer of our own groundbreaking solutions. Our products ...
Enables long term cell storage at -80°C or -196°C. Improved cell recovery and viability after thawing. Ready-to-use freezing media – no programmed or sequential freezing required. Serum-free – no risk of contamination. GMP ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene ...
based inPessac, FRANCE
We bring together biophysicists, stem cell biologists & bioproduction engineers around the motto 'Cell Therapy for All'. TreeFrog Therapeutics was created to provide access to safe, efficient and affordable cell therapies for millions of patients. ...
$100,000 Funding: We fund your research over 2 years in the academic lab of your choice. You spend the money how you like on your project, so that you can give it your best shot. Just Science: Any PhD level scientist can apply anonymously by ...
based inBangkok, THAILAND
The Regeneration Center provides comprehensive and scientifically backed stem cell treatments for numerous conditions and degenerative diseases. Through years of research and clinical applications of modern cellular therapeutics our internationally ...
Several clinical studies have clearly demonstrated the benefits of stem cells. Peer-reviewed medical journals today are intent on finding the richest source of stem cells in the human body. Researchers have found that umbilical cord blood is rich ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for ...
based inVirum, DENMARK
Immudex was created in 2009 when it spun off from the diagnostic company Dako, now Agilent. Since then, Immudex has grown in numbers, employees, patents, product lines, partnerships, and customers served. Research, development, and commercial ...
based inCambridge, MASSACHUSETTS (USA)
We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. Vor, the Norse goddess of wisdom, was known as the careful one. ...
VOR33 is our lead eHSC product candidate designed to replace the standard of care in transplant settings. Once the VOR33 cells have engrafted, we believe that patients can be treated with anti-CD33 therapies, such as Mylotarg or VCAR33, with limited ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
MIT-001 is an innovative clinical candidate that blocks the root cause of graft-versus-host disease, which often occurs during allogenic hematopoietic stem cell transplantation (HSCT), through a ...
based inGrove City, OHIO (USA)
Forge is developing innovative gene therapies that aim to help patients suffering from devastating rare diseases. Forge is building capacity to directly address the growing demand for gene therapy manufacturing. Forge is currently building the ...
Krabbe disease is a devastating neurodegenerative disease affecting about 1 -2.5 in 100,000 people in the U.S. and is inherited in an autosomal recessive manner. Krabbe disease is caused by loss-of-function mutations in the galactosylceramidase ...
based inCarlsbad, CALIFORNIA (USA)
TargaZyme is a clinical-stage biotechnology company based in San Diego, CA and focused on the research and development of disruptive and novel, off-the-shelf T-Cell products that are aimed at improving the efficacy of T-cell therapies by delivering ...
TZ 102, like all of TargaZyme’s therapeutics, is an off-the-shelf product for point-of-care use. It’s made of two (2) components, fucosyltransferase VII enzyme and GDP ...
based inMalvern, PENNSYLVANIA (USA)
Ocugen Inc. (NASDAQ: OCGN) is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19. Our breakthrough modifier gene therapy platform ...
OCU400 (AAV-NR2E3) is a novel gene therapy product candidate with the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases (“IRDs”). It consists of ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
Ushering in the Future of NK-cell Therapy: Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant ...
based inMountain View, CALIFORNIA (USA)
Osel’s mission is to develop and commercialize a broad portfolio of Live Biotherapeutic Products (LBPs) that prevent or treat abnormal conditions resulting from a disruption of the human microbiome. In 2003, Osel was one of the first companies to ...
CBM588 is an orally-administered Clostridium butyricum strain with a long history of clinical use and safety in all age groups in Japan. In Japan, CBM588 has primarily been used to treat infectious and noninfectious diarrheal disorders associated ...
based inRapperswil, SWITZERLAND
Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders. ...
Aplastic anemia is a rare, but serious hematological disease caused by a failure or deficiency of the bone marrow to produce blood cells (erythrocytes, leukocytes, and platelets). Patients with aplastic anemia are at risk of ...
based inNew York, NEW YORK (USA)
IN8bio was founded in 2016 with the mission of developing novel therapies to address cancer. The company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product ...
INB-100, our DeltEx Allo, is an allogeneic product candidate, initially developed for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation (HSCT). This is ...
based inShanghai, CHINA
Focusing on the core raw materials of the life science industry, Yeasen Biotechnology (Shanghai) Co., Ltd. is a biotechnology company engaged in the research and development, production and sales of three major categories of biological reagents: ...
D-luciferin is a common substrate for Luciferase and is widely used throughout biotechnology, especially in vivo imaging technology. The mechanism of action is that luciferin (the substrate) is oxidized to emit light in response to ATP and ...
based inMarlborough, MASSACHUSETTS (USA)
Verax Biomedical is a privately held, venture backed medical products company, founded in 1999. The Company’s laboratory facilities are located in Marlborough, Massachusetts, just west of Boston. Our vision is to create rapid tests that are ...
Stem cells, activated leukocytes and other cellular therapies are another area of obvious applicability for PGD technology as these cells are grown in media that also support bacterial ...
based inSeattle, WASHINGTON (USA)
Universal Cells is a Seattle-based company that is producing engineered stem cell lines that can avoid rejection and be used in allogeneic cell therapy treatments for the people who need them. One Cell, Many Therapies. Universal Cells edits genes ...
Realizing the potential of pluripotent stem cells requires that the therapeutic cells derived from PSCs be accepted by patients. PSC-derived cells that have not been engineered to ...
based inCambridge, MASSACHUSETTS (USA)
Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human ...
SER-155 is an investigational, oral, rationally designed, fermented microbiome therapeutic designed to reduce the incidence of gastrointestinal infections, bacteremia, and graft versus host disease (GvHD) in immunocompromised patients, including ...
based inHamburg, GERMANY
Revvity Gene Delivery (formerly SIRION Biotech) supports your cell and gene therapy development process ̶ offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production. ...